Introduction
Lyme disease, the most common vector-borne disease in the United States (1) , is caused by the spirochete Borrelia burgdorferi , sensu lato (2) . The disease is transmitted to humans most often by the bite of an infected Ixodes tick and is characterized by the initial appearance of distinctive erythema migrans (EM) 1 skin lesions in 60-80% of patients (3, 4) . Key early and late clinical manifestations reflecting dissemination to visceral targets include lymphadenopathy, arthritis, neurological manifestations, and carditis (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . Periods of chronicity and recurrent attacks in the untreated patient often occur (11, 14) . The development and evaluation of an efficacious vaccine against this complex disease and its etiologic agent mandate a thorough understanding of spirochetal virulence and pathogenesis. Although characterization of B. burgdorferi surface molecules is far from complete, attempts have been made to develop effective vaccinogens using membrane lipoproteins (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . The major focus has been on the most abundant of these lipoproteins, designated outer surface protein A (OspA), which has been shown to be predominantly located in the periplasmic space (25) . OspA has been successful in inducing a high degree of protective immunity in mice and dogs against needle and/or heterologous tick challenge (15) (16) (17) (18) (20) (21) (22) (23) (24) . It has been shown that after tick challenge, the antibodies generated by these vaccinated animals are sufficient to eliminate the spirochetes in the tick vector before they can infect the host (21, 22) . In previous studies, we have shown for the first time that EM, as well as persistent skin infection and visceral dissemination, can be induced in the rabbit after intradermal injection of B. burgdorferi (26) . Within 5 mo, the infection clears and the animals exhibit a high degree of immunity to reinfection (26) . Thus, the rabbit provides a unique model in which protective immunity to B. burgdorferi can be assessed whether acquired by infection or by vaccination with individual or combined B. burgdorferi molecules.
In an effort to determine whether molecules other than the recombinant OspA presently being evaluated in human trials may be efficacious as protective immunogens, we conducted a study in the rabbit in which we compared OspA and infectionderived immunity. We show that intradermal challenge of infection-immune rabbits with 10 6 B. burgdorferi, strain B31, sensu stricto, results in a greater degree of homologous protection compared with that obtained in the OspA vaccinated rabbits. The status of immunity among both the OspA vaccinated and infection-immune groups did not correlate with antiOspA antibodies as measured by ELISA. Further, completely resistant infection-immune rabbits exhibited significantly lower prechallenge titers than susceptible OspA vaccinated rabbits at the same timepoint. These data support the concept that efficacious vaccines can be developed that circumvent the limitations associated with OspA immunization.
Methods
Experimental animals. Adult male New Zealand white rabbits 6-9 mo of age (Irish Farms, Norco, CA) were housed individually in a temperature controlled environment ranging from 18-21 Њ C. Before each intradermal inoculation and challenge with B. burgdorferi , the backs of the rabbits were clipped closely with an electric clipper fitted with a size 40 blade to expose the skin (Oster Professional Products, McMinnville, TN).
Immunization of rabbits with OspA. Rabbits were vaccinated with a recombinant OspA lipoprotein adsorbed onto aluminum hydroxide (alum) and with alum alone kindly supplied by SmithKline Beecham Biologicals (Rixensart, Belgium). The vaccinogen and alum preparations were diluted to appropriate concentration with PBS buffer containing 5 mM K 2 HPO 4 , 5 mM NaH 2 PO 4 , and 150 mM NaCl adjusted to pH 6.7. Rabbits received three intramuscular injections administered at 2-wk intervals; each injection contained 10 g of OspA vaccine in 1.0 ml of PBS diluent, pH 6.7. As sham controls, rabbits were inoculated as described with a total of three doses of alum contained in 1.0 ml of diluent per dose.
Production of infection-derived immune rabbits. On the basis of previous studies in which a high degree of infection-derived immunity to challenge was established (26) , rabbits were infected intradermally with 6 ϫ 10 7 virulent B. burgdorferi , strain B31, sensu stricto, passage 4. 7 mo after infection, at a time when EM and dermal infection could not be detected by culture of skin biopsies and, on the basis of previously described studies, visceral dissemination was no longer demonstrable (26) , the rabbits were challenged as described below.
Preparation of the challenge inoculum. Virulent B. burgdorferi , strain B31, sensu stricto, was isolated from infected rabbit tissue, grown in BSK II medium (27) to maximum density, and then passaged twice more in fresh medium. After the final passage (passage 2), the organisms were centrifuged, washed three times in heat-inactivated normal rabbit serum diluted 1:1 in PBS, pH 7.2 (NRS-PBS), allowed to sit at room temperature for 15 minutes after each centrifugation and resuspension, and then adjusted with NRS-PBS to the concentration required for challenge after the final wash (26) .
Challenge with B. burgdorferi. 4 wk after the final booster, the immunized, sham control, naive control, and infection-derived immune rabbits were challenged intradermally at 10 sites on the clipped back. Each site received 10 5 B. burgdorferi , strain B31, sensu stricto, passage 2 contained in 0.1 ml of modified BSK II prepared as described above. The animals were examined daily for the presence of EM lesions. At defined time points described below, skin biopsies for culture were obtained from both representative EM lesions and from representative dermal sites of those animals in which EM lesions did not appear. Similarly, popliteal lymph nodes, joint tissue, and spinal cord were removed from representative rabbits in each group and cultured as described below. For future immunopathogenesis studies, skin biopsies were obtained from 17 and 16 random sites on four rabbits in each of the sham and naive control groups, respectively, before the expected time of EM appearance. As a result, these sites could not be included in the observations relating to EM formation. The presence or absence of EM at an additional two sites on two sham vaccinated rabbits could not be determined due to heavy fur growth at the sites.
Skin biopsy procedures. Skin biopsies were carried out on random sites on each rabbit at the time of EM development in the control animals (usually 7 d) and at 19-22 d postchallenge. Rabbits were anesthetized by intramuscular injection with 45 mg Ketaset (Fort Dodge Laboratories, Fort Dodge, IA) and 8.8 mg Xylazine (Lloyd Laboratories, Shenandoah, IA) per kilogram body weight. Clipped backs were disinfected with 70% ethanol and 3% hydrogen peroxide. Two 4-5-mm punch biopsies adjacent to the inoculation site (Baker and Cummings, Lakewood, NJ) were taken from each rabbit. Each biopsied specimen was immediately placed on ice in a sterile Petri dish and then processed within 1 h for culture and future studies.
Tissue removal for dissemination studies. At 19-22-d postchallenge, rabbits were anesthetized as described above and exsanguinated from the central artery. The popliteal lymph nodes, spinal cord, and joint tissue surrounding the patella were aseptically removed immediately upon killing, placed on ice in a sterile Petri dish, and then processed for culture and future studies within 2 h. The spinal cord was exposed by removal of the dorsal portion of the vertebrae with sterile instruments. After exposure, the cord was raised with a sterile spatula, severed with a sterile scalpel, and a portion removed. For joint removal, the skin over the surface of the hind legs of the rabbit was clipped with an electric clipper, sterilized with 70% ethanol, and removed. The tendons above the patella were severed with a sterile scalpel and the joint tissue was then removed with a sterile forceps and sterile scalpel.
Culture of tissues from immunized and control rabbits. Representative portions of each tissue were divided into ‫ف‬ 5-mm sections, minced, and then placed into 5 ml of BSK II medium containing 100 g/ml phosphomycin and 50 g/ml rifampin (28) . Cultures were incubated at 34 Њ C for a period of 30 d, and the presence or absence of B. burgdorferi was determined by darkfield microscopy. Cultures were considered negative when no spirochetes were observed during the 30-d observation period. 100 l of blood was cultured and examined in a similar fashion.
Sera for ELISA. Blood was obtained aseptically from the central artery of the control and experimental rabbits before vaccination (basals), before challenge, and at postchallenge time points. The sera were separated by centrifugation, aliquoted, and stored individually at Ϫ 70 Њ C until ready for use.
ELISA. The ELISA was carried out as previously described with minor modifications (26) . Flat bottomed, 96-well immunoassay plates (Immulon 4; Dynatech Laboratories, Inc., Chantilly, VA) were coated overnight at room temperature in a humidified chamber with 100 l of 1 g/ml recombinant OspA antigen kindly supplied by SmithKline Beecham Biologicals. The plates were washed twice with wash buffer (0.5% Tween 20 in PBS) and blocked for 1 h with Blotto (5% dry nonfat milk in PBS). After two washes with wash buffer, 100 l of twofold dilutions of rabbit serum in PBS ranging from 1:500 to 1:320,000 were added in duplicate to the wells and incubated at room temperature for 2 h. Plates were washed four times, incubated with goat antirabbit immunoglobulin conjugated to horseradish peroxidase, and diluted to 1:5,000 or 1:2,000, respectively (Amersham Corp., Arlington Heights, IL). The plates were then washed four times and 100 l of 2,2 Ј -azinobis (3-ethyl benzthiazoline sulfonic acid) peroxidase substrate system (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD) was added to each well. After 30 min, the OD of each well was measured at 405 nm on an automated ELISA plate reader (Titertek Multiscan MCC/340; Flow Laboratories, Baar, Switzerland). Serum from an OspA immunized rabbit was chosen as a positive standard to measure interassay variability. This serum was run in serial dilution on each plate, and the mean and standard deviation of each dilution determined; the standard deviation was found to be Յ 0.03 at the tested dilutions.
Statistical analyses. Proportions were compared by the chi square method. Mean log anti-OspA ELISA titers were compared by the t test. Statistical significance was determined by P Ͻ 0.05.
Results
Protection of rabbits conferred by OspA vaccination. As shown in Table I Protection of rabbits conferred by infection. A statistically significant degree of acquired resistance was also demonstrable among the challenged infection-immune rabbits compared with the challenged naive control animals (chi square value ϭ 17; d.f. ϭ 2; P ϭ 0.0001). As shown in Table I , only 2 of the 11 infection-derived immune rabbits showed evidence of infection; each of the remaining 9 rabbits was completely immune to EM and dermal infection, while the 7 animals in this group that were tested showed complete immunity to visceral dissemination. Even among the two animals that failed to exhibit a complete immunity, the organisms did not generate an EM response, produced dermal infection at only 5 of 22 cultured sites, and remained localized to the skin.
Comparative degree of protection between OspA vaccinated and infection-immune rabbits. A higher degree of resistance against B. burgdorferi challenge was observed among the infection-immune rabbits (9 of 11 ϭ 81.8%) compared with OspA vaccinated animals (7 of 11 ϭ 63.6%). However, this difference was not statistically significant ( P Ͼ 0.05). Nonetheless, it should be noted that while 4 of 11 OspA vaccinated rabbits developed both EM and dissemination, none of the 11 challenged infection-immune rabbits exhibited these clinical manifestations (chi square value ϭ 4.9; d.f. ϭ 1; P ϭ 0.03).
Relationship between status of immunity and ELISA antiOspA antibody titers. No significant differences in prechallenge ELISA anti-OspA titers were observed between the susceptible and immune OspA vaccinated rabbits ( P Ͼ 0.05). Prechallenge titers of 1:320,000 were observed in two of the four susceptible and four of the seven immune rabbits (Table II) .
There was also no correlation found between the status of immunity of the infection-immune rabbits and their prechallenge ELISA anti-OspA titers ( P Ͼ 0.05). The two animals susceptible to dermal infection upon challenge exhibited titers of 1:5,000 and 1:10,000, whereas among the nine rabbits immune to EM, dermal infection, and/or visceral dissemination, only one showed a higher titer (1:20,000); the remaining immune animals exhibited titers ranging from 1:1,000 to 1:10,000 (Table II) . Similarly, there was no correlation between immune status and ELISA anti-OspA titers observed among both the OspA vaccinated and infection-immune animals at 7 d and 3-4 wk postchallenge ( P Ͼ 0.05; Table II ).
Discussion
We recently described a rabbit model of Lyme disease with two novel features (26) . First, intradermal injection of B. burgdorferi consistently induced lesions with the appearance and histological features of erythema migrans. The rabbit is the only animal model besides the rhesus monkey (29) that produces EM, and the only model in which EM consistently appears. Second, within 5 mo of infection, rabbits had cleared EM as well as dermal and visceral infection and exhibited immunity to reinfection (26) . In this report, we have employed each of these key features of the rabbit model in comparing infection-derived immunity with immunity acquired by immunization with OspA.
Our findings represent the first extensive assessment of EM with regard to protection conferred by an OspA vaccine in an animal model. As in many studies with rodents (15-18, 21, 22), OspA immunization of rabbits conferred significant resistance against B. burgdorferi infection. The fact that the protection was incomplete is of considerable interest. It should be noted that early studies with OspA immunization of mice demonstrated that complete protection of mice was evident when 10 4 or fewer spirochetes were used in intradermal or intraperitoneal challenge. However, challenge with larger numbers of B. burgdorferi resulted in incomplete or no protection (17) . Subsequent studies have used challenge doses of 10 4 or fewer (16, 30) . In our previous characterization of infectionderived immunity, rabbits challenged with as many as 8 ϫ 10 7 virulent B. burgdorferi demonstrated solid immunity. In this study, we challenged rabbits with considerably fewer organisms, 10 5 at each of 10 sites for a total of 10 6 B. burgdorferi per rabbit. When comparing the high dose of challenge that can be administered to previously infected animals that subsequently demonstrate complete protection with our findings of partial protection conferred by OspA immunization, the contrast is of particular interest. While each of the four OspA immunized rabbits susceptible to infection exhibited EM, it is noteworthy that EM occurred at relatively few (1-4) of the 10 intradermal inoculation sites. While the appearance of EM at the inoculated sites was variable, dermal infection and dissemination were evident in each of these four animals. The two infected rabbits in the infection-immune group developed dermal infection without EM or visceral infection. Taken together, these observations indicate that states of partial immunity may be acquired in the rabbit; in the partially immune animal, protection against EM could be accompanied by chronic skin and/or visceral infection with B. burgdorferi.
Lyme disease in humans is a chronic infection which, after months to years, may lead to disease manifestations such as arthritis, neurological illness, and carditis (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . As a result, the potential consequences of vaccination resulting in partial immunity, namely, establishment of infection without the development of EM, must be considered. In this study, we report that two infection-derived immune rabbits developed dermal infection upon challenge despite failure to develop EM lesions and visceral dissemination (Table I) . A vaccine that permits the survival of organisms in tissues without producing EM after exposure allows the establishment of chronicity in the absence of the characteristic skin lesion that prompts patients to seek treatment. This potential "masking" could result in the later development of debilitating disease. Further, these observations, together with our finding that complete infectionderived immunity can wane after 7 mo with only dermal infection upon challenge, emphasize the necessity for evaluating the need for booster doses. Of further relevance are the potential consequences of vaccination that may lead to seronegative infection. Luft et al. have described how unsuccessful treatment of EM with azithromycin led to recurrent infection marked by seronegativity, while those patients in whom azithromycin or amoxicillin prevented relapse were more likely to become seropositive (31) . These data also support the possibility that a state of partial immunity generated by vaccination may "mask" infection that develops in the absence of EM and seropositivity.
We cannot definitively address why OspA vaccination did not confer complete immunity. As considered above, we suspect that greater protection would have been apparent had lesser numbers of B. burgdorferi been used in the challenge inoculum. There was no statistical difference between the ELISA anti-OspA titers of the immune and susceptible rabbits. However, it is possible that antibodies to OspA epitopes most closely linked with borreliacidal activity (32) did exhibit significant variance among the animals and may relate causally to the varying degrees of protection observed. Unlike inbred mice used in the rodent challenge experiments (15) (16) (17) (18) (21) (22) (23) (24) , rabbits are outbred animals and would be expected to respond to antigens in a more variable manner.
Our findings regarding infection-derived immunity confirm and extend our initial observations (26) , where complete protection against challenge with 8 ϫ 10 7 low passage B. burgdorferi, strain B31 was observed 5 mo after initial infection. In this study, challenge with 10 6 low passage B. burgdorferi, strain B31 was conducted 7 mo after infection. Highly significant protection resulted but, because skin infection in the absence of EM and dissemination resulted in 2 of the 11 rabbits, infection-derived immunity may have waned after 7 mo. There was no statistically significant difference between the numbers of fully immune and susceptible rabbits in the infection-immune and OspA vaccinated groups. However, the observation that all the susceptible OspA rabbits developed EM and disseminated infection while the infection-immune group developed only a dermal infection is significant. This may perhaps indicate a greater degree of protective immunity in the infection immune rabbits.
While the relative degree of protection acquired by OspA vaccination compared with that acquired by previous infection may be arguable, the difference in prechallenge anti-OspA titers between the groups was striking. ELISA anti-OspA titers ranged from 1:1,000 to 1:20,000 in the infection-immune rabbits compared with 1:160,000 to 1:320,000 in the immune OspA vaccinated rabbits (Table II) . These findings are consistent with the possibility that acquired resistance may be generated by molecules other than OspA. We have recently identified sev-eral virulent associated outer membrane proteins that might be targets of protective immunity (33) . Other investigators have obtained data that are in agreement with this observation (34, 35) . In the study conducted by Barthold and Bockenstedt (36) , mice were passively protected with mouse sera generated from mice injected with varying doses of inoculum. They concluded that the protection generated appeared to be unrelated to antibody to OspA. In the study conducted by Aydintug et al. (34) , they observed that sera obtained from monkeys infected by tick feeding demonstrated antibody-dependent complementmediated killing despite the lack of anti-OspA and -OspB antibodies in this serum.
While OspA has been shown to have considerable efficacy as a vaccinogen by several investigators (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) , there has been a growing appreciation of the potential limitations in its use in this regard. Recently, evidence has accumulated that OspA is not expressed during vertebrate infection (37) , and OspA vaccinated inbred mice have been shown to be susceptible to infection derived from skin implants taken from infected syngeneic animals (38) . The antigenic heterogeneity of OspA among strains (39-42) is well known, and the potential for significant numbers of OspA escape mutants after vaccination and challenge have been described (40) , along with the failure to provide cross protection by needle inoculation against strains with OspA genotypes different from the vaccinogen (23, 30) . In addition, B. burgdorferi may persist in animals with relatively high antibody titers (34, 42 , and this study), and a decline of anti-OspA antibody titers occurs with time despite persistent infection (34) .
This study highlights potential limitations of the OspA vaccine and underscores the notion that quantitatively greater degrees of protection may be conferred by immunization with the molecules responsible for infection-derived immunity. Our view is that recently described outer membrane spanning (Oms) proteins, including porins (33) , may prove to be attractive vaccine candidates that might be used alone or in combination with the OspA protein to provide a higher degree of protection against larger inocula and strains of differing OspA serotypes.
